Trends
AstraZeneca in AI collaboration with Immunai to inform cancer drug trials
OUR TAKEAstraZeneca has entered into an $18 million agreement with Immunai to use its artificial intelligence model to improve the efficiency of its cancer drug trials. The collaboration is part of AstraZeneca’s continued efforts to integrate AI into drug development, following a significant $247 mi…
Headline
OUR TAKEAstraZeneca has entered into an $18 million agreement with Immunai to use its artificial intelligence model to improve the efficiency of its cancer drug trials. The collaboration is part of AstraZeneca’s continued efforts to integrate AI into drug development, following…
Context
OUR TAKE AstraZeneca has entered into an $18 million agreement with Immunai to use its artificial intelligence model to improve the efficiency of its cancer drug trials. The collaboration is part of AstraZeneca’s continued efforts to integrate AI into drug development, following a significant $247 million deal last year to develop cancer-fighting antibodies. Immunai, a New York-based biotech company, specialises in decoding the immune system using single-cell genomics and AI to revolutionise clinical decision-making in oncology. –Heidi Luo, BTW reporter AstraZeneca has announced an $18 million collaboration with New York-based biotechnology company Immunai to use its advanced AI model of the immune system. The partnership aims to streamline cancer drug development and make clinical trials more efficient.
Evidence
Pending intelligence enrichment.
Analysis
Founded in 2018, Immunai combines single-cell genomics and machine learning to improve the development of new therapeutics by comprehensively analysing the immune system. In the first phase of the collaboration, AstraZeneca will gain access to Immunai’s state-of-the-art AI platform. This access is expected to provide AstraZeneca with valuable insights into the mechanisms of action of immunotherapies. According to AstraZeneca’s chief data scientist for oncology R&D, Iker Huerga, the collaboration will focus on key areas of clinical decision-making, including dose selection and biomarker identification, which are critical to optimising treatment efficacy. Also read: Appfire’s owners explore stake sale in collaboration software maker
Key Points
- AstraZeneca is investing $18 million in Immunai Inc to use AI to improve the efficiency of cancer drug trials.
- The collaboration will improve clinical decision-making in oncology, focusing on dose selection and biomarker identification.
Actions
Pending intelligence enrichment.
